

DAFTAR PUSTAKA

1. Kwon YS, Koh WJ. Diagnosis and treatment of nontuberculous mycobacterial lung disease. *J Korean Med Sci.* 2016;31(5):649–59.
2. Namkoong H, Kurashima A, Morimoto K, Hoshino Y, Hasegawa N, Ato M, et al. Epidemiology of pulmonary nontuberculous mycobacterial disease, Japan. *Emerg Infect Dis.* 2016;22(6):1116–7.
3. Ratnatunga CN, Lutzky VP, Kupz A, Doolan DL, Reid DW, Field M, et al. The rise of non-tuberculosis mycobacterial lung disease. *Front Immunol.* 2020;11:1–12.
4. Winthrop KL, Marras TK, Adjemian J, Zhang H, Wang P, Zhang Q. Incidence and prevalence of nontuberculous mycobacterial lung disease in a large U.S. managed care health plan, 2008-2015. *Ann Am Thorac Soc.* 2020;17(2):178–85.
5. Wassilew N, Hoffmann H, Andrejak C, Lange C. Pulmonary disease caused by non-tuberculous mycobacteria. *Respiration.* 2016;91(5):386–402.
6. Sharma SK, Upadhyay V. Epidemiology, diagnosis & treatment of non-tuberculous mycobacterial diseases. *Indian J Med Res.* 2020;152(3):185–226.
7. Lee H, Myung W, Koh WJ, Moon SM, Jhun BW. Epidemiology of nontuberculous mycobacterial infection, South Korea, 2007-2016. *Emerg Infect Dis.* 2019;25(3):569–72.
8. Saptawati L, Kusumo H, Suryawati B. Prevalence of non-tuberculous mycobacteria (NTM) in Surakarta, Indonesia: higher than expected. *KnE Life Sci.* 2019;4(12):132–8.
9. Surekha KRM, Srikumar BPS, Kumar AM. Assessment of hematological parameters in pulmonary tuberculosis patients. *Indian J Clin Biochem.* 2016;31(3):332–5.
10. Li F, Chen D, Zeng Q, Du Y Du. Possible mechanisms of lymphopenia in severe tuberculosis. *Microorganisms.* 2023;11(11):1–4.
11. Huang HL, Cheng MH, Lu PL, Shu CC, Wang JY, Wang JT, et al. Epidemiology and predictors of NTM Pulmonary Infection in Taiwan - A retrospective, five-year multicenter study. *Sci Rep.* 2017;7(1):1–8.
12. Yao L, Gui X, Wu X, Yang J, Fang Y, Sun Q, et al. Rapid Identification of Nontuberculous Mycobacterium Species from Respiratory Specimens Using Nucleotide MALDI-TOF MS. *Microorganisms.* 2023;11(8).
13. Lake MA, Ambrose LR, Lipman MCI, Lowe DM. ' "Why me, why now?"

Using clinical immunology and epidemiology to explain who gets nontuberculous mycobacterial infection. *BMC Med.* 2016;14:1–13.

14. Park Y, Kwak SH, Yong SH, Lee SH, Leem AY, Kim SY, et al. The association between behavioral risk factors and nontuberculous mycobacterial pulmonary disease. 2021;62(8):702–7.
15. Deflorio-barker S, Egorov A, Smith GS, Murphy MS, Jason E, Ghio AJ, et al. Environmental risk factors associated with pulmonary isolation of nontuberculous mycobacteria, a population-based study in the Southeastern United States. *Sci Total Environ.* 2022;763:1–22.
16. Wang J, Xu H, Wang X, Lan J. Rapid diagnosis of non-tuberculous mycobacterial pulmonary diseases by metagenomic next-generation sequencing in non-referral hospitals. *Front Cell Infect Microbiol.* 2023;12(1):1–14.
17. Matsumoto Y, Kinjo T, Motooka D, Nabeya D, Jung N, Uechi K, et al. Comprehensive subspecies identification of 175 nontuberculous mycobacteria species based on 7547 genomic profiles. *Emerg Microbes Infect.* 2019;8(1):1043–53.
18. Marras TK, Mendelson D, Marchand-Austin A, May K, Jamieson FB. Pulmonary nontuberculous mycobacterial disease, Ontario, Canada, 1998–2010. *Emerg Infect Dis.* 2013;19(11):1889–91.
19. Mertaniasih N, Kusumaningrum D, Koendhori E, Soedarsono, Kusmiati T, Dewi D. Nontuberculous mycobacterial species and *Mycobacterium tuberculosis* complex coinfection in patients with pulmonary tuberculosis in Dr. Soetomo Hospital, Surabaya, Indonesia. *Int J Mycobacteriology.* 2017;6(1):9–13.
20. Saptawati L, Primaningtyas W, Dirgahayu P, Sutanto YS, Wasita B, Suryawati B, et al. Characteristics of clinical isolates of nontuberculous mycobacteria in Java-Indonesia: A multicenter study. *PLoS Negl Trop Dis.* 2022;16(12):1–17.
21. Bastos L, Nogueira C, Santos M, Moraes MB De, Shu P, Martins C. Non-tuberculous cutaneous mycobacterioses. *An Bras Dermatol.* 2021;96(5):527–38.
22. Maboni G, Prakash N. Review of methods for detection and characterization of non-tuberculous mycobacteria in aquatic organisms. *J Vet Diagnostic Investig.* 2023;36(3):1–13.
23. Johnson MM, Odell JA. Nontuberculous mycobacterial pulmonary infections. *J Thorac Dis.* 2014;6(3):210–20.
24. Tran T, Bonham AJ, Chan ED, Honda JR. A paucity of knowledge regarding nontuberculous mycobacterial lipids compared to the tubercle bacillus. *Tuberculosis.* 2019;115:96–107.

25. Faria S, Joao I, Jordao L. General overview on nontuberculous mycobacteria, biofilms and human infection. *J Pathog.* 2015;2015:1–10.
26. American Lung Association. Learn About NTM Lung Disease [Internet]. 2023 [cited 2024 Feb 15]. Available from: <https://www.lung.org/lung-health-diseases/lung-disease-lookup/nontuberculous-mycobacteria/learn-about-nontuberculosis-mycobacteria>
27. Gramegna A, Lombardi A, Lorè NI, Amati F, Barone I, Azzarà C, et al. Innate and adaptive lymphocytes in non-tuberculous mycobacteria lung disease : a review. *Front Immunol.* 2022;13:1–9.
28. Restiawati NM, Burhan E. Diagnosis dan penatalaksanaan mycobacterium other than tuberculosis (MOTT). *J Respirologi Indones.* 2011;31(2):156–64.
29. Wang DM, Liu H, Zheng YL, Xu YH, Liao Y. Epidemiology of Nontuberculous mycobacteria in tuberculosis suspects, Southwest of China, 2017-2022. *Front Cell Infect Microbiol.* 2023;13(1):1–10.
30. Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DR. Prevalence of nontuberculous mycobacterial lung Disease in U.S. medicare beneficiaries. *Am J Respir Crit Care Med.* 2012;185(8):881–6.
31. Shu C chung, Wu M fang, Pan S wei, Wu TS, Lai HC, Lin MC. Host immune response against environmental nontuberculous mycobacteria and the risk populations of nontuberculous mycobacterial lung disease. *J Formos Med Assoc.* 2020;119(5):S13–22.
32. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. *Am J Respir Crit Care Med.* 2007;175(4):367–416.
33. Kim SJ, Yoon SH, Choi SM, Lee J, Lee C hoon, Han SK. Characteristics associated with progression in patients with of nontuberculous mycobacterial lung disease : a prospective cohort study. *BMC Pulm Med.* 2017;17(1):1–8.
34. McShane PJ, Glassroth J. Pulmonary disease due to nontuberculous mycobacteria current state and new insights. *Chest.* 2015;148(6):1517–27.
35. Kamei R, Sawahata M, Nakayama M, Yamada T, Taniguchi N, Bando M, et al. Prevalence of systemic and local risk factors for pulmonary non-tuberculous mycobacterial disease in Japan: a single-institution study. *J Rural Med.* 2023;18(3):168–74.
36. Johnston JC, Chiang L, Elwood K. *Mycobacterium kansasii*. *Microbiol Spectr.* 2017;5(1):1–9.
37. Prasla Z, Sutliff RL, Sadikot RT. Macrophage signaling pathways in

- pulmonary nontuberculous mycobacteria infections. *Am J Respir cell Microbiol.* 2020;63(2):144–51.
38. Prevots DR, Marras KT. Epidemiology of human pulmonary infection with non-tuberculous mycobacteria: A review. *Neuron.* 2015;36(1):1–31.
 39. Pennington KM, Vu A, Challener D, Rivera CG, Shweta FNU, Zeuli JD, et al. Approach to the diagnosis and treatment of non-tuberculous mycobacterial disease. *J Clin Tuberc Other Mycobact Dis.* 2021;24:1–16.
 40. Prevots DR, Loddenkemper R, Sotgiu G, Migliori GB. Nontuberculous mycobacterial pulmonary disease: An increasing burden with substantial costs. *Eur Respir J.* 2017;49:1–5.
 41. Pathak K, Hart S, Lande L. Nontuberculous Mycobacteria Lung Disease (NTM-LD): Current recommendations on diagnosis, treatment, and patient management. *Int J Gen Med.* 2022;15:7619–29.
 42. Kumar VG, Urs TA, Ranganath RR. MPT 64 Antigen detection for rapid confirmation of *M.tuberculosis* isolates. *BMC Res Notes.* 2011;4(1):1–4.
 43. Mediavilla-Gradolph MC, De Toro-Peinado I, Bermúdez-Ruiz MP, García-Martínez MDLÁ, Ortega-Torres M, Montiel Quezel-Guerraz N, et al. Use of MALDI-TOF MS for Identification of Nontuberculous Mycobacterium Species Isolated from Clinical Specimens. *Biomed Res Int.* 2015;2015:1–6.
 44. Sharma M, Malhotra B, Tiwari J, Bhargava S. Profile of nontuberculous mycobacteria in patients suspected of tuberculosis and drug-resistant tuberculosis. *J Lab Physicians.* 2020;12(3):203–11.
 45. Menkes RI. Keputusan menteri kesehatan republik indonesia nomor HK.01. 07/MENKES/5675/2021 tentang data penduduk sasaran program pembangunan kesehatan.
 46. WHO. The asia – pacific perspective: redefining obesity and its treatment. 2000. 1–56 p.
 47. Tigner A, Ibrahim S, Murray I. Histology, white blood cell. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2014. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK563148/%0A>
 48. Uno S, Asakura T, Morimoto K, Yoshimura K, Uwamino Y, Nishimura T, et al. Comorbidities associated with nontuberculous mycobacterial disease in Japanese adults: a claims-data analysis. *BMC Pulm Med.* 2020;20(1):1–8.
 49. Russell CD, Claxton P, Doig C, Seagar AL, Rayner A, Laurenson IF. Non-tuberculous mycobacteria: A retrospective review of Scottish isolates from 2000 to 2010. *Thorax.* 2013;69(6):593–5.
 50. Moore JE, Kruijshaar ME, Ormerod LP, Drobniewski F, Abubakar I. Increasing reports of non-tuberculous mycobacteria in England, Wales and

- Northern Ireland, 1995-2006. *BMC Public Health*. 2010;10(1):1–6.
51. Lim AYH, Chotirmall SH, Fok ETK, Verma A, De PP, Goh SK, et al. Profiling non-tuberculous mycobacteria in an Asian setting: characteristics and clinical outcomes of hospitalized patients in Singapore. *BMC Pulm Med*. 2018;18(1):1–7.
 52. Wang X, Li T, Liu Y, Zhu Y, Chen L, Gao Y. Clinical characteristics of patients with nontuberculous mycobacterium pulmonary disease in Fuyang, China: A retrospective study. *Infect Drug Resist*. 2024;17(1):3989–4000.
 53. Kim JY, Kim NY, Jung HW, Yim JJ, Kwak N. Old age is associated with worse treatment outcome and frequent adverse drug reaction in mycobacterium avium complex pulmonary disease. *BMC Pulm Med*. 2022;22(1):1–9.
 54. Liu Q, Du J, An H, Li X, Guo D, Li J, et al. Clinical characteristics of patients with non-tuberculous mycobacterial pulmonary disease: a seven-year follow-up study conducted in a certain tertiary hospital in Beijing. *Front Cell Infect Microbiol*. 2023;13(1):1–14.
 55. Kim JY, Han A, Lee H, Ha J, Lee KW, Suh KS, et al. The clinical course and prognosis of patients with nontuberculous mycobacterial pulmonary disease after solid organ transplantation. *J Korean Med Sci*. 2023;38(6):1–9.
 56. Dohál M, Porvazník I, Krivošová M, Solovič I, Mokry J. Epidemiology of non-tuberculous mycobacterial diseases in Slovakia during the years 2016–2021. *Respir Physiol Neurobiol*. 2023;314(1):1–5.
 57. Mirsaeidi M, Sadikot RT. Gender susceptibility to mycobacterial infections in patients with non-CF bronchiectasis. *Int J Mycobacteriology*. 2015;4(2):1–7.
 58. Tan Y, Su B, Shu W, Cai X, Kuang S, Kuang H, et al. Epidemiology of pulmonary disease due to nontuberculous mycobacteria in Southern China, 2013-2016. *BMC Pulm Med*. 2018;18(1):1–7.
 59. Reed C, Reyn CF von, Chamblee S, Ellerbrock T V, Johnson JW, Marsh BJ, et al. Environmental risk factors for infection with mycobacterium avium complex. *Am J Epidemiol*. 2006;164(1):32–40.
 60. Maekawa K, Ito Y, Hirai T, Kubo T, Imai S, Tatsumi S, et al. Environmental risk factors for pulmonary mycobacterium avium-intracellulare complex disease. *Chest*. 2011;140(3):723–9.
 61. Foote SL, Lipner EM, Prevots DR, Ricotta EE. Environmental predictors of pulmonary nontuberculous mycobacteria (NTM) sputum positivity among persons with cystic fibrosis in the state of Florida. *PLOS*. 2021;16(1):1–9.
 62. Song JH, Kim BS, Kwak N, Han K, Yim JJ. Impact of body mass index on

- development of nontuberculous mycobacterial pulmonary disease. *Eur Respir J*. 2021;57(2):1–12.
63. Glodic G, Samarzija M, Sabol I, Bulat Kardum L, Careviv Vladić V, Džubur F, et al. Risk factors for nontuberculous mycobacterial pulmonary disease (NTM-PD) in Croatia. *Wien Klin Wochenschr*. 2021;133(21–22):1195–200.
 64. Jhun BW, Moon SM, Jeon K, Jung Kwon O, Yoo H, Carriere KC, et al. Prognostic factors associated with long-term mortality in 1445 patients with nontuberculous mycobacterial pulmonary disease: a 15-year follow-up study. *Eur Respir J*. 2020;55(1):1–9.
 65. Hu C, Huang L, Cai M, Wang W, Shi X, Chen W. Characterization of nontuberculous mycobacterial pulmonary disease in Nanjing district of China. *BMC Infect Dis*. 2019;19(1):1–8.
 66. Ghali A El, Morrisette T, Alosaimy S, Lucas K, Tupayachi-Ortiz MG, Vemula R, et al. Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomes. *Antimicrob Agents Chemother*. 2023;67(10):1–13.
 67. Varley CD, Henkle E, Strnad L, Ku J, Brunon A, Winthrop K. Laboratory abnormalities among patients with pulmonary mycobacterium avium complex infections. *Open forum Infect Dis*. 2019;6(2):1–8.
 68. Dasaradhan T, Koneti J, Kalluru R, Gadde S, Cherukuri S priya, Chikatimalla R. Tuberculosis-associated anemia: A narrative review. *Cureus*. 2022;14(8):1–8.
 69. Kotey SK, Tan X, Fleming O, Kasiraju RR, Dagnell AL, Van Pelt KN, et al. Intracellular iron accumulation facilitates mycobacterial infection in old mouse macrophages. *GeroScience*. 2024;46(1):2739–54.
 70. Tishkowski K, Gupta V. Erythrocyte Sedimentation Rate. *StatPearls [internet]*; 2023. 1–5 p.
 71. Hwang H, Lee JK, Heo EY, Kim DK, Lee HW. The factors associated with mortality and progressive disease of nontuberculous mycobacterial lung disease: a systematic review and meta-analysis. *Sci Rep*. 2023;13(1):1–16.
 72. Hachisu Y, Murata K, Takei K, Tsuchiya T, Tsurumaki H, Koga Y, et al. Prognostic nutritional index as a predictor of mortality in nontuberculous mycobacterial lung disease. *J Thorac Dis*. 2020;12(6):3101–9.
 73. Sanogo F, Kodio O, Sarro YS, Diarra B, Coulibaly G, Tolofoudie M, et al. Hematological profiles of patients with tuberculosis and nontuberculous mycobacteria infections in Bamako, Mali. *Int J Mycobacteriology*. 2023;12(3):235–40.

74. Faldt J, Dahlgren C, Ridell M. Difference in neutrophil cytokine production induced by pathogenic and non-pathogenic mycobacteria. *APMIS*. 2002;110(9):1–8.
75. Nakamura K, Nakayama H, Sasaki S, Takahashi K, Iwabuchi K. Mycobacterium avium-intracellulare complex promote release of pro-inflammatory enzymes matrix metalloproteinases by inducing neutrophil extracellular trap formation. *Sci Rep*. 2022;12(1):1–12.
76. Frajman A, Izhakian S, Mekiten O, Hadar O, Lichtenstadt A, Hajaj C, et al. Phenotypical characteristics of nontuberculous mycobacterial infection in patients with bronchiectasis. *Respir Res*. 2024;25(1):1–8.
77. Gebreweld A, Fiseha T, Kebede E, Tamir Z, Gebremariam B, Miruts F, et al. Immuno-hematological and biochemical changes in patients with tuberculosis in Dessie Comprehensive Specialized Hospital, Dessie, Ethiopia. *J Blood Med*. 2024;15(1):147–55.
78. Middleton EA, Weyrich AS, Zimmerman GA. Platelets in pulmonary immune responses and inflammatory lung diseases. *Physiol Rev*. 2016;96(4):1211–59.
79. Guo Y, Cao Y, Liu H, Yang J, Wang W, Wang B, et al. Clinical and microbiological characteristics of Mycobacterium kansasii pulmonary infections in China. *Microbiol Spectr*. 2022;10(1):1–13.
80. Hsu D, Irfan M, Jabeen K, Iqbal N, Hasan R, Migliori GB, et al. Post tuberculosis treatment infectious complications. *Int J Infect Dis*. 2020;92(1):S41–5.
81. Gai X, Allwood B, Sun Y. Post-tuberculosis lung disease and chronic obstructive pulmonary disease. *Chin Med J (Engl)*. 2023;136(16):1923–8.
82. Jeon DS, Kim S, Kim MA, Chong YP, Shim TS, Jung CH, et al. Type 2 diabetes mellitus and complication-related risk of nontuberculous mycobacterial disease in a south korean cohort. *Microbiol Spectr*. 2023;11(2):1–11.
83. Toth E, Waller JL, Bollag WB, Siddiqui B, Mohammed A, Kheda M, et al. Non-tuberculous mycobacterial infections in patients with end-stage renal disease: Prevalence, risk factors, and mortality. *J Investig Med*. 2023;71(7):707–15.